Contrasting GeoVax Labs (NASDAQ:GOVX) & Biomea Fusion (NASDAQ:BMEA)

Biomea Fusion (NASDAQ:BMEA) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and price targets for Biomea Fusion and GeoVax Labs, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biomea Fusion	0	2	6	0	2.75
GeoVax Labs	0	0	1	0	3.00

Biomea Fusion presently has a consensus price target of $53.13, indicating a potential upside of 318.64%. GeoVax Labs has a consensus price target of $120.00, indicating a potential upside of 6,028.39%. Given GeoVax Labs’ stronger consensus rating and higher probable upside, analysts clearly believe GeoVax Labs is more favorable than Biomea Fusion.

Insider and Institutional Ownership

96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are owned by institutional investors. 26.3% of Biomea Fusion shares are owned by insiders. Comparatively, 4.0% of GeoVax Labs shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Biomea Fusion has a beta of -0.53, meaning that its stock price is 153% less volatile than the S&P 500. Comparatively, GeoVax Labs has a beta of 2.89, meaning that its stock price is 189% more volatile than the S&P 500.

Profitability

This table compares Biomea Fusion and GeoVax Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biomea Fusion	N/A	-69.35%	-59.65%
GeoVax Labs	N/A	-189.16%	-140.10%

Valuation & Earnings

This table compares Biomea Fusion and GeoVax Labs’ revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biomea Fusion	N/A	N/A	-$117.25 million	($3.46)	-3.69
GeoVax Labs	$80,000.00	51.00	-$25.97 million	($13.34)	-0.14

GeoVax Labs has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Summary

Biomea Fusion beats GeoVax Labs on 6 of the 11 factors compared between the two stocks.

About Biomea Fusion

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.

About GeoVax Labs

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.